GlassScriptPhysician profile
Michel Kuzur
NPI 1083659163
$35,242.04
in general payments reported to CMS, 2019-2025
64 companies · $1,736 in 2025
The $1,736 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $4,254 · 2021: $11.92 · 2022: $10K · 2023: $3,764 · 2024: $2,650 · 2025: $1,736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,370 · Consulting Fee: $3,640 · Education: $99.95 · Travel and Lodging: $39.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,369.62 |
| Consulting Fee | $3,640.00 |
| Education | $99.95 |
| Travel and Lodging | $39.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $11,307.84 | 2019-2025 | Imfinzi, Calquence, Lynparza |
| Cti Biopharma Corp. | $5,267.40 | 2022-2023 | Vonjo |
| Eisai INC. | $4,961.13 | 2019-2025 | |
| Pharmacosmos Therapeutics INC. | $2,440.17 | 2022-2024 | Cosela |
| Bayer Healthcare Pharmaceuticals INC. | $1,763.88 | 2019-2025 | |
| Janssen Biotech, INC. | $1,755.37 | 2019-2025 | Darzalex, Imbruvica, Tecvayli |
| Merck Sharp & Dohme LLC | $785.21 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Seagen INC. | $611.01 | 2019-2023 | Tukysa, Adcetris |
| Novartis Pharmaceuticals Corporation | $451.85 | 2019-2025 | |
| Beigene, LTD. | $450.00 | 2020 | |
| Pfizer INC. | $376.49 | 2019-2025 | |
| Athenex Pharmaceutical Division, LLC | $350.00 | 2020 | |
| Amgen INC. | $324.65 | 2019-2023 | Kyprolis |
| Alexion Pharmaceuticals, INC. | $322.65 | 2022-2025 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $311.46 | 2019-2025 | Opdivo, Opdualag |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $285.16 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Regeneron Healthcare Solutions, INC. | $284.70 | 2023-2025 | Libtayo |
| Novocure Gmbh | $250.00 | 2022 | |
| Gilead Sciences, INC. | $231.40 | 2019-2025 | Trodelvy |
| Daiichi Sankyo INC. | $221.89 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Genentech USA, INC. | $196.15 | 2019-2025 | Lunsumio, Polivy, Tecentriq |
| Pharmaessentia USA Corporation | $153.52 | 2023-2025 | Besremi |
| Takeda Pharmaceuticals U.S.A., INC. | $144.58 | 2019-2025 | Ninlaro, Alunbrig |
| Exelixis INC. | $132.81 | 2019-2025 | Cabometyx |
| Beigene USA, INC. | $130.31 | 2023-2025 | Brukinsa |
| Lilly USA, LLC | $122.08 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Aveo Pharmaceuticals, INC. | $109.25 | 2023-2025 | Fotivda |
| Astellas Pharma US INC | $108.18 | 2019-2025 | Xospata, Vyloy |
| Genzyme Corporation | $104.30 | 2019-2024 | |
| Incyte Corporation | $103.33 | 2019-2025 | Monjuvi, Zynyz, Pemazyre |
| Array Biopharma INC | $85.92 | 2024-2025 | Lorbrena, Braftovi, Mektovi |
| Taiho Oncology, INC. | $77.99 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $66.50 | 2019 | |
| Glaxosmithkline, LLC. | $64.02 | 2024-2025 | Ojjaara |
| Rigel Pharmaceuticals, INC. | $59.81 | 2019-2024 | Tavalisse, Rezlidhia |
| Tersera Therapeutics LLC | $59.38 | 2023-2024 | Zoladex, Xermelo |
| Blueprint Medicines Corporation | $52.26 | 2020-2023 | Ayvakit |
| Teva Pharmaceuticals USA, INC. | $49.45 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.50 | 2024-2025 | Gilotrif |
| Jazz Pharmaceuticals INC. | $43.10 | 2020-2024 | |
| Beone Medicines USA, INC. | $42.84 | 2025 | Tevimbra, Brukinsa |
| Biocompatibles, INC. | $38.89 | 2019 | |
| Sobi, INC | $38.70 | 2024-2025 | |
| Stemline Therapeutics INC. | $38.68 | 2020-2023 | Orserdu |
| Apellis Pharmaceuticals, INC. | $36.62 | 2023 | Empaveli |
| Tempus Ai, INC | $30.15 | 2025 | Xt Cdx |
| Novocure INC. | $28.49 | 2022 | |
| Puma Biotechnology, INC. | $27.30 | 2019-2023 | |
| Ipsen Biopharmaceuticals, INC | $26.63 | 2019 | |
| Dova Pharmaceuticals | $26.49 | 2019-2020 | |
| Genmab U.S., INC. | $25.54 | 2025 | Epkinly |
| Janssen Pharmaceuticals, INC | $23.69 | 2023 | Xarelto |
| G1 Therapeutics, INC. | $22.86 | 2023 | Cosela |
| Sumitomo Pharma America, INC. | $20.98 | 2025 | Orgovyx |
| Emd Serono, INC. | $20.35 | 2024 | |
| Cycle Pharmaceuticals INC | $18.36 | 2025 | Phyrago |
| Mirati Therapeutics, INC. | $18.26 | 2023 | Krazati |
| Aurobindo Pharma USA, INC. | $16.89 | 2019 | |
| Spectrum Pharmaceuticals INC. | $15.12 | 2019 | |
| Kite Pharma, INC. | $14.74 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $12.49 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.22 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $12.18 | 2019 | |
| Foundation Medicine, INC. | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michel Kuzur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.